Diabetes Update - American Diabetes Association
2006
Medical Author:
Ruchi Mathur, MD, FRCP(C)
Medical Editor:
Jay W. Marks, MD
The American Diabetes Association's (ADA) annual 66th
Scientific Sessions were recently held in Washington DC. The meeting brought
close to 18,000 health professionals together to discuss issues related to
diabetes (type 1, type 2
and gestational diabetes),
prediabetes , metabolic syndrome, and other related disease processes. Topics of interest ranged from trying to understand the
pathophysiology of
disease (what happens in the body that causes diabetes to develop) to new ways
to prevent and treat diabetes including both pharmacotherapy with drugs, and
with lifestyle intervention.
The interesting thing about the ADA annual meeting is that many different
types of health care providers attend the meetings -- MDs, PhDs, researchers, nutritionists, educators, nurses, and community health workers.
Each of these professional groups make a commitment to work together to help
treat and prevent diabetes. A team approach is really the only way to attempt to
conquer diabetes, which at present affects about 20 million of us in the U. S.
alone.
While some of the science presented at symposia was novel and very exciting,
particularly advances in beta cell preservation and transplantation (beta cells
are the cells that produce insulin) ,I would like to focus on some of the newer
therapies that were discussed at the ADA meeting, and tell you about what's
up-and-coming in the realm of treatment for diabetes. For the sake of length,
I've chosen 3 topics I think will be interesting for the majority of readers:
glucose sensors, a new class of drugs called DPP-IV inhibitors and inhaled
insulin.
Continuous Glucose Sensors
One of the major advances this year was in the development of technology for
continuous glucose sensors. A sensor is a device that is inserted into the
subcutaneous fat (just beneath the
skin) in the abdomen or upper arm. After calibration with glucose measurements
obtained from blood, the sensor then
provides real-time glucose readings at five minute intervals. Some of the
sensors display a graph for watching trends in blood sugar levels.
Other sensors allow for warning beeps to be programmed before blood sugars get
too high or to low. Some sensors even calculate the rate of change of blood
sugar, allowing a patient to anticipate upcoming hypoglycemic events. Other sensors, such as the
model by Medtronic, work especially well with the insulin pump. In this case,
the sensor sends a signal directly to the pump which then performs calculations
to determine a suggested course of action--which the patient must then approve.
A sensor is ideal for patients using insulin pumps, patients prone to large
fluctuations in blood glucose, athletes, those with hypoglycemia (particularly at
night), or anyone wanting to better understand the relationship between daily
activity and food intake with blood glucose levels.
As diabetologists, our goal is to provide our patients with therapies that
mimic natural physiology as closely as possible. Aside from successful
transplantation or regeneration of the body's insulin producing cells, the
ultimate goal is an artificial pancreas
that senses the body's sugar level and responds immediately with the appropriate
amount of insulin needed to keep blood sugar in the normal range. We are not there yet but are getting closer.